| UHC UMR Medical and Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Gazyva® (Obinutuzumab) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Genetic Testing for Neurological Disorders - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Home Health, Skilled, and Custodial Care Services - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Natalizumab (Tyruko® & Tysabri®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Indications - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Gazyva® (Obinutuzumab) - Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Genetic Testing for Neurological Disorders - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Home Health, Skilled, and Custodial Care Services - Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Natalizumab (Tyruko® & Tysabri®) - Commercial Medical Benefit Drug Policy | 2026-01-01 |